Timely & critical insights across the spectrum of pharma & biotech

HomeCategory

Patented Drugs & Vaccines

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/09/Samsung-Bioepis-640x480.jpg

Patented Drugs & Vaccines R & D, Regulatory & Policy

Samsung’s Byooviz receives EMA approval

September 1, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/07/US-FDA-approves-fexinidazole-as-the-first-all-oral-treatment-for-sleeping-sickness-640x480.png

Patented Drugs & Vaccines R & D, Regulatory & Policy

US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness

July 29, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/07/PF_Pfizer-640x480.jpg

COVID-19 Patented Drugs & Vaccines

Pfizer and BioNTech Partner with Biovac to supply COVID-19 Vaccine in Africa

July 22, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/07/PF_IPSEN-640x480.jpg

Deals Patented Drugs & Vaccines

Ipsen Enters Exclusive Worldwide Licensing Agreement with IRLAB

July 21, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/07/novo-nordisk-prothena-640x480.jpg

Deals Patented Drugs & Vaccines

Novo Nordisk acquires ATTR Amyloidosis program for USD 1.2 Bn

July 14, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/07/Emergency-Use-Authorization-1-640x480.jpg

Patented Drugs & Vaccines R & D, Regulatory & Policy

Actemera receives FDA EUA to treat hospitalized COVID-19 patients

July 8, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/07/Walmart-Insulin-640x480.jpg

Patented Drugs & Vaccines

Walmart Launches Low-Priced Private Label Insulin

July 2, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/06/Biogen-640x480.jpg

Patented Drugs & Vaccines R & D, Regulatory & Policy

Alzheimer’s drug, ADUHELM™ receives Approval by the US FDA

June 9, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/06/Celltrion-Iksuda-640x480.jpg

Deals Patented Drugs & Vaccines

Celltrion – Mirrae Asset Group pour USD 47 million in ADC developer Iksuda Therapeutics

June 8, 20210

https://www.sathguru.com/pharmforward/wp-content/uploads/2021/06/therapeutic-areas-640x480.jpg

Deals Patented Drugs & Vaccines

Centessa Announces Pricing of IPO to Fund Drug Development

June 4, 20210